Morris AD, Elsayed ME, Ponnusamy A, et al. - Since the benefits of treating anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) in advancing age remains uncertain with most published studies identifying elderly as ≥ 65 years, researchers conducted this meta-analysis to determine outcomes of induction immunosuppression in patients aged ≥ 75 years. Between 2006 and 2018, a cohort of patients aged ≥ 75 years with a diagnosis of AAV was constructed from two centres. Sixty-seven patients [mean age was 79 ± 2.9 years] have been identified. The authors discovered that patients ≥75 years with AAV benefit from induction immunosuppression with a significant survival benefit. When considering treatment, age alone should not be a limiting factor.